Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Summary

04/19/2018 NOTE: Some sites may be enrolling into Group 2 alone. Please contact the site for verification. The purpose of this phase I study is to determine the safety and tolerability of MVT-5873 as a monotherapy and with GemAbraxane in patients with pancreatic cancer or other CA19-9 positive malignancies.

General Information

NCT#: NCT02672917
Study ID: MV-0715-CP-001.01
Trial Phase: Phase I

Trial Sponsor: MabVax Therapeutics, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, MVT-5873

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search